Biomarkers for prostate cancer detection

Amanda Beth Reed, Dipen J. Parekh

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarkers are needed for detecting prostate cancer and for determining which cancers need to be treated. This review will discuss the development of new biomarkers for prostate cancer detection and disease prognostication, focusing on recent progress and particular topical issues related to the development and validation of these new markers.

Original languageEnglish (US)
Pages (from-to)103-114
Number of pages12
JournalExpert Review of Anticancer Therapy
Issue number1
StatePublished - Jan 2010
Externally publishedYes


  • Biomarkers
  • Cancer
  • PSA
  • Prostate
  • Prostate-specific antigen
  • Tumor markers

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Biomarkers for prostate cancer detection'. Together they form a unique fingerprint.

Cite this